Sign In

Friday, January 19, 2018 - 8:00 am to Saturday, January 20, 2018 - 12:00 pm

Industry Colloquium: Novel Targets and Therapies in Liver Disease

Note: CME was not provided.

Conference Description/Needs Statement

This conference will focus on therapeutic developments from the perspective of clinical and translational investigators and regulatory professionals. Participants will gain insight into novel therapies and the regulatory landscape for a variety of liver diseases with robust therapeutic pipelines. In addition, attendees will have opportunities to discuss the latest on biomarkers and the design of treatment studies for these diseases.

Program Chairs

  • Michael W. Fried, MD, FAASLD
  • Kris V. Kowdley, MD, FAASLD

Location

  • Bethesda North Marriott
    Rockville, MD

Learning Objectives

  • Therapeutic developments from the perspective of clinical and translational investigators and regulatory professionals
  • Novel therapies and the regulatory landscape for a variety of liver diseases with robust therapeutic pipelines
  • The latest in biomarkers and the design of treatment studies for these diseases

Session I: NASH

Friday, January 19, 2018

Moderators: Lara L. Dimick-Santos, MD and Arun J. Sanyal, MD, FAASLD

  • 7 am
    Breakfast
  • 8–8:20 am
    Noninvasive Markers for Nonalcoholic Steatohepatitis
    Arun J. Sanyal, MD, FAASLD
  • 8:20–8:40 am
    Introducing NASH-related Health Measures in Population Health Studies
    Zobair M. Younossi, MD, MPH, FAASLD
  • 8:40–9 am
    Demonstrating Effectiveness of NASH Interventions and Road to Combination Therapies
    Stephen A. Harrison, MD, FAASLD
  • 9–9:20 am
    Prioritizing Therapy for NASH:  Lessons Learned From HCV
    Mary E. Rinella, MD, FAASLD
  • 9:20–9:50 am
    Panel Discussion
  • 9:50–10:20 am
    Break

Session II: Cholestatic Liver Diseases

Friday, January 19, 2018

Moderators: Cynthia Levy, MD, FAASLD and David Jones, PhD

  • 10:20–10:40 am
    Pathways and Targets of Cholestatic Liver Disease
    David Jones, PhD
  • 10:40–11 am
    Current Drug Development for PBC and PSC
    Michael H. Trauner, MD, FAASLD
  • 11–11:20 am
    Neoadjuvant Chemoradiotherapy Followed by Liver Transplantation for Hilar Cholangiocarcinoma
    Julie Heimbach, MD 
  • 11:20–11:40 am
    Surrogate Endpoints for Drug Development in Cholestatic Liver Diseases
    Cynthia Levy, MD, FAASLD 
  • 11:40 am–12:10 pm
    Panel Discussion
  • 12:15–1:45 pm
    Lunch and Poster Viewing

Session III: Portal HTN

Friday, January 19, 2018

Moderators: Guadalupe Garcia-Tsao, MD, FAASLD and Juan G. Abraldes, MD

  • 1:45–2:05 pm
    Therapeutic Target and Drugs-Experimental Models in Portal Hypertension
    Jonel Trebicka, MD, PhD
  • 2:05–2:25 pm
    Candidate Drugs: Human Studies
    Guadalupe Garcia-Tsao, MD, FAASLD
  • 2:25–2:45 pm
    Clinical Trial Design in Portal HTN
    Juan G. Abraldes, MD
  • 2:45–3:15 pm
    Panel Discussion
  • 3:15–3:45 pm
    Break

Session IV: Cirrhosis

Friday, January 19, 2018

Moderators: Meena B. Bansal, MD and Naga P. Chalasani, MD, FAASLD

  • 3:45–4:05 pm 
    Assessment of PK/PD and Toxicity in Cirrhotic Patients
    Naga P. Chalasani, MD, FAASLD
  • 4:05–4:25 pm 
    Intermediate Surrogate Markers for Therapeutic Response in Patients with Cirrhosis
    Meena B. Bansal, MD
  • 4:25–4:45 pm 
    Assessing Long-term Outcomes After Therapeutic Interventions in Patients with Cirrhosis
    Joseph K. Lim, MD, FAASLD
  • 4:45–5:15 pm 
    Panel Discussion
  • 5:15-6:15 pm
    Reception

Session V: Hepatocellular Carcinoma

Saturday, January 20, 2017

Moderators: Lewis R. Roberts, MBChB, PhD, FAASLD and Margit Naomi Horiba, MD, MPH 

  • 7 am
    Breakfast
  • 8–8:20 am
    Progress in Biomarkers for HCC
    Jorge A. Marrero, MD
  • 8:20–8:40 am
    Kinase Inhibitors, Immunotherapies, and Other Systemic Therapies
    Lewis R. Roberts, MBChB, PhD, FAASLD
  • 8:40–9 am
    Measuring Success in Combination Therapies
    Laura M. Kulik, MD
  • 9–9:30 am
    Panel Discussion 
  • 9:30–10 am
    Break

Session VI: Hepatitis B

Saturday, January 20, 2017

Moderators: Adam Gehring, PhD and Anna S. Lok, MD, FAASLD

  • 10–10:20 am
    Preclinical Phase Drugs to Treat Chronic Hepatitis B: Does Anything Really Work? How Can We Know?
    Timothy M. Block, PhD
  • 10:20–10:40 am
    Hepatitis B: Early Phase Clinical Studies of Novel Antiviral Therapies
    Anna S. Lok, MD, FAASLD
  • 10:40–11 am
    Early Phase Clinical Studies of Immunomodulatory Agents
    Adam Gehring, PhD
  • 11–11:20 am
    Pathway to Combination Therapy: Endpoints and Challenges
    Poonam Mishra, MD, MPH
  • 11:20–11:50 am
    Panel Discussion
  • 11:50 am-Noon
    Wrap-up and Adjourn